Loading...
circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway
Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated that circular RNAs play a crucial role in chemoresi...
Na minha lista:
| Udgivet i: | Mol Ther Nucleic Acids |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Gene & Cell Therapy
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7452060/ https://ncbi.nlm.nih.gov/pubmed/32805491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2020.07.027 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|